Success Metrics

Active Trials

4(80%)

Phase Distribution

Ph phase_1

80%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Recruiting4

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 14 (80.0%)

Phase 31 (20.0%)

Trials by Status

not_yet_recruiting120%

recruiting480%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095

not_yet_recruitingphase_1

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895

recruitingphase_1

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069

recruitingphase_1

A Study of ZL-1310 in Participants With Selected Solid Tumors

NCT06885281

recruitingphase_3

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146

Clinical Trials (5)

Showing 5 of 5 trials

NCT07531095Phase 1

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Recruiting

NCT07707895Phase 1

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Not Yet Recruiting

NCT06179069Phase 1

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Recruiting

NCT06885281Phase 1

A Study of ZL-1310 in Participants With Selected Solid Tumors

Recruiting

NCT07218146Phase 3

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5